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The regulatory role of epidermal permeability barrier function in cutaneous inﬂammation has been well
appreciated. While barrier disruption induces cutaneous inﬂammation, improvement of permeability
barrier function alleviates inﬂammation. Studies have demonstrated that improvement of epidermal
permeability barrier function not only prevents the development of atopic eczema, but also delays the
relapse of these diseases. Moreover, enhancing the epidermal permeability barrier also alleviates atopic
eczema. Furthermore, co-applications of barrier enhancing products with glucocorticoids can increase
the therapeutic efﬁcacy and reduce the adverse effects of glucocorticoids in the treatment of atopic
eczema. Therefore, utilization of permeability barrier enhancing products alone or in combination with
glucocorticoids could be a valuable approach in the treatment of atopic eczema. In this review, we discuss
the beneﬁts of improving the epidermal permeability barrier in the management of atopic eczema.
Copyright © 2015, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
The epidermal permeability barrier is one of the most crucial
protective functions of the skin and is primarily mediated by stra-
tum corneum lipids and differentiation-related proteins. Stratum
corneum lipids consist mainly of an equal molar ratio of cholesterol,
fatty acids, and ceramides. The major differentiation-related pro-
teins include ﬁlaggrin, involucrin, and loricrin. Alteration of either
epidermal lipid metabolism or epidermal differentiation can affect
permeability barrier function. Conversely, permeability barrier re-
quirements regulate a wide range of epidermal metabolic pro-
cesses, including epidermal proliferation, differentiation, lipid
production, oxidative stress, as well as antimicrobial defense.
Moreover, the role of the epidermal permeability barrier in regu-
lating cutaneous inﬂammation has been well demonstrated by our
group and others. Recent studies have indicated that permeability
barrier function is closely associated with the development of
certain inﬂammatory skin disorders accompanied by permeabilityy have no ﬁnancial or non-
atter or materials discussed
), 4150 Clement Street, San
).
cal Association. Published by Elsevbarrier abnormalities, such as atopic dermatitis, contact dermatitis,
and psoriasis.1,2 Improving epidermal permeability barrier function
has proved effective in treating atopic dermatitis.3 Additionally,
preventive beneﬁts of enhancing permeability barrier function for
atopic dermatitis have also been demonstrated. However, the
importance of enhancing permeability barrier function in the
management of atopic eczema is still undervalued. In this article,
we review the beneﬁts of enhancing permeability barrier strategies
in atopic eczema.Regulatory role of the epidermal permeability barrier in
cutaneous inﬂammation
Clinically, inﬂammatory dermatoses often exhibit a defective
permeability barrier. Although it is not clear whether a primary
immunologic defect results in defective barrier or vice versa, it is
clear that barrier disruption stimulates cytokine production and
release. Tumor necrosis factor (TNF) a is expressed primarily in the
upper epidermis in normal mouse skin. After acute barrier
disruption with either acetone or tape-stripping, TNFa expression
increases throughout all of the nucleated epidermal cell layers. This
increase in TNFa expression, as well as several other keratinocyte-
derived cytokines, occurs as early as 2 hours after acute barrier
disruption.4,5 Likewise, TNFa expression is also increased in the
epidermis of essential fatty acid deﬁcient (EFAD) mice, whichier Taiwan LLC. All rights reserved.
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protein expression, the expression levels of TNFa mRNA are maxi-
mally increased (> 20-fold) 1 hour after acute barrier disruption
and return to normal levels by 8 hours.5 Moreover, the expression
levels of mRNA for TNF p55 receptor are also upregulated in acute
barrier abrogation with either acetone or tape-stripping, and in
EFAD mice.6 By contrast, barrier abrogation does not alter the
expression levels of epidermal TNFb mRNA.6 Although barrier
abrogation increases TNFa expression, artiﬁcial restoration of the
permeability barrier with a vapor impermeablemembrane does not
prevent the increase in expression levels of either protein or mRNA
for TNFa in acetone-treated7 and normal skin.8 However, in chronic
inﬂammation, such as occurs in EFAD mice, occlusion with a vapor
impermeable membrane lowers epidermal interleukin-1 (IL-1)a
and TNFa mRNA levels.7
IL-1a is another major proinﬂammatory cytokine in the skin.
Acute barrier disruption increases IL-1a expression in both the
dermis and epidermis 10 minutes after tape-stripping and returns
to normal levels by 24 hours. Similarly, a higher expression level of
IL-1a exists in both the dermis and epidermis of EFAD mice.8 In
contrast to TNFa, occlusion of normal skin for 48 hours decreases
epidermal IL-1a expression. Additionally, following tape-stripping,
the expression levels of epidermal IL-1a are lower in preoccluded
than nonoccluded mouse skin.8 Tape-stripping-induced increases
in IL-1a expression are likely to be released from a preformed pool,
because the expression levels of epidermal IL-1a at room temper-
ature are comparable to that at 4

C.8 Ito et al9 reported that UVB
irradiation of barrier-disrupted skin enhanced the expression of IL-
1b by Langerhans cells. These results suggest that the impact of the
permeability barrier on cytokine expression varies with the type of
cytokine. Upregulation of epidermal mRNA for cytokines was also
demonstrated in humans.10 It is worth noting that following tape-
stripping of mouse skin, mRNA levels for IFNg remained un-
changed in mouse epidermis, while they increase signiﬁcantly in
humans.6,10 The inﬂuences of the permeability barrier on cytokine
expression are summarized in Table 1.4e11
In addition, the permeability barrier also inﬂuences the inﬁl-
tration of inﬂammatory cells. It is well known that the levels of
histamine content are higher in atopic skin than normal controls,
and that histamine is mainly from mast cells. Our study showedTable 1 Inﬂuences of barrier disruption on epidermal cytokine expression.
Cytokines Methods of barrier disruption Refs
Tape-stripping Acetone EFAD
TNFa Protein [ [ [ 4,5,10
mRNA [ [ [ 5,6,10
TNFb mRNA () N/D () 6
IL-1a Protein [ N/D [ 8
mRNA [ [ [ 5,6,10
IL-1b mRNA [ [ [ 5,6
IL-2 mRNA () N/D N/D 6,10
IL-3 mRNA () N/D N/D 6
IL-4 mRNA () N/D N/D 6,10
IL-5 mRNA () N/D N/D 6,10
IL-6 mRNA [ N/D [ 6
IL-8 mRNA [ N/D N/D 10
IL-10 mRNA [ N/D N/D 10
IFN g mRNA () N/D () 6
GMCSF mRNA [ [ [ 5
TNF (p55) receptor mRNA [ [ [ 7
IL-1ra receptor mRNA [ [ [ 5,11
IL-1 (p60) receptor mRNA () N/D () 6
IL-6 receptor mRNA () N/D () 6
IFN g receptor mRNA () N/D () 6
EFAD ¼ essential fatty acid deﬁcient; GMCSF ¼ granulocyte-macrophage colony
stimulating factor; IFN ¼ interferon; IL ¼ interleukin; IL-1ra ¼ IL-1 receptor
antagonist; TNF ¼ tumor necrosis factor.that barrier disruption induced > 45% increase in mast cell density
in the dermis.12 The Langerhans cells are critical in the develop-
ment of cutaneous inﬂammation, including atopic dermatitis.
Proksch and Brasch13 showed that barrier disruption with acetone,
sodium dodecyl sulfate, or tape-stripping induced > 90% increase in
epidermal Langerhans cell density 24 hours after treatment.
Moreover, epidermal Langerhans cell density positively correlated
with the extent of barrier abnormality.13 However, occlusion with a
vapor impermeable membrane prevented the increased Langer-
hans cell density induced by barrier disruption.14 Barrier disruption
with either acetone or tape-stripping increases the expression of
major histocompatibility complex class II antigens, B7-2 and
intercellular adhesion molecule-1 on Langerhans cells.15e17 Topical
application of an allergen (nickel sulfate 5%) to barrier disrupted
skin causes a further increase in epidermal Langerhans cell density
compared to normal intact skin or barrier disrupted skin without
allergen application.13 Furthermore, barrier disruption with either
acetone or tape-stripping causes a > 60% increase in cutaneous
contact sensitivity to 1-ﬂuoro-2,4-dinitrobenzene, picryl chloride,
and contact photosensitivity, in addition to the induction of a > 1.5-
fold increase in T cell proliferation.16 Taken together, barrier
disruption stimulates cytokine production, increases inﬂammatory
inﬁltrate, and stimulates Langerhans cell maturation and T cell
proliferation.
Products that improve the epidermal permeability barrier
and their potential mechanisms of action
There are many products that can improve epidermal permeability
barrier function via divergent mechanisms. The active ingredients
of those products include stratum cornum physiologic lipids
(cholesterol, fatty acids, and ceramides), petrolatum, glycerol, an-
tioxidants, urea, and certain plant extracts. These ingredients can
be used alone or in combination with others. Optimal ratios of
stratum corneum lipids can improve permeability barrier resulting
from formation of membrane bilayers, the lipid barrier in the
stratum corneum.17e20 By contrast, topical petrolatum forms a
hydrophobic barrier in the stratum corneum, but does not pene-
trate into deeper layers of the stratum corneum.21 The improve-
ment of the permeability barrier by antioxidants can be attributed
to the stimulation of epidermal differentiation, lipid production,
antimicrobial defense, and antioxidation capacity.22e25 However,
the mechanisms by which glycerol regulates permeability barrier
homeostasis are not clear.26,27 The commonly used ingredients that
improve permeability barrier for atopic dermatitis are listed in
Table 2.17e32
Therapeutic beneﬁts of enhancing permeability barrier for
atopic eczema
Physiological lipids
As stated above, barrier disruption increases inﬂammation while
artiﬁcial restoration barrier inhibits inﬂammation. Accordingly,
improvement of permeability barrier function could be a logical
approach to treat inﬂammatory dermatoses. Indeed, clinical studies
have demonstrated that enhancing permeability barrier function
beneﬁts certain inﬂammatory skin disorders, including atopic
dermatitis. For example, topical applications of TriCeram (Cerage-
nix Pharmaceuticals, Inc., Denver, CO, USA), containing optimal
ratios of stratum corneum lipids (cholesterol, ceramide, and fatty
acids), twice daily for 3 weeks induced > 25% reduction in Severity
Scoring of Atopic Dermatitis (SCORAD) in parallel with a decrease in
transepidermal water loss (TEWL), which positively correlates with
SCORAD, in children with atopic dermatitis.3,33 Similarly, topical
Table 2 The commonly used ingredients that improve barrier function and potential mechanisms of their actions.
Ingredients Mechanisms of action Refs
SC lipids Formation of membrane bilayers, upregulation of antimicrobial peptide expression 17e20
Petrolatum Formation of hydrophobic barrier 21
Antioxidants Anti-oxidative stress, stimulation of differentiation and lipid production, upregulation
of antimicrobial peptide expression
22e25
Glycerol Accelerating barrier recovery via unknown mechanism 26,27
a Sunﬂower oil, coconut oil, evening primrose oil,
olive oil, and borage oil
Stimulation of differentiation and lipid production, upregulation of antimicrobial
peptide expression
28,29
Hyaluronic acid Stimulation of differentiation and lipid production 30,31
Urea Stimulation of differentiation and antimicrobial peptide expression 32
a These oils contain a substantial portion of linoleic acid. (http://www.uccs.edu/Documents/danderso/fats_oils.pdf), which exhibits the properties of peroxisome
proliferation-activation receptor a and g (PPARa/g) ligands. Thus, the beneﬁts of these oils on the permeability barrier are largely attributed to the activation of PPAR a/g.
(http://www.uccs.edu/Documents/danderso/fats_oils.pdf).
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amide, and fatty acids) twice daily for 8 weeks induced a 77%
reduction in disease severity of atopic dermatitis in addition
to > 80% reduction in disease severity of irritant contact dermatitis
and allergic contact dermatitis.34 The efﬁcacy of topical lipid
mixture alone is comparable to that of conventional immuno-
modulators.35,36 For example, topical applications of TriCeram for 4
weeks induced a 33% reduction in TEWL while topical 0.1% tacro-
limus ointment caused a 36% reduction in atopic dermatitis.35
Moreover, TriCeram and 0.1% tacrolimus ointment displayed
similar efﬁcacies on the expression of epidermal antimicrobial
peptides (human defensin 2 and cathelicidin-related antimicrobial
peptides) after 4 weeks of treatment for atopic dermatitis.35 A
combination of topical stratum corneum lipid mixture and gluco-
corticoids is more effective for improving erythema in irritant
contact dermatitis, allergic contact dermatitis, and atopic derma-
titis.34 However, the addition of petrolatum to stratum corneum
lipid mixture does not further improve the therapeutic efﬁcacy for
chronic eczema.37 By contrast, addition of hyaluronic acid to stra-
tum corneum lipid mixture achieves a better efﬁcacy than stratum
corneum lipid mixture alone in the treatment of atopic derma-
titis.38 Additional studies on the efﬁcacy of topical lipids for atopic
dermatitis are listed in Table 3.3,33e39
In addition to topical applications, the oral ingredient of lipids,
including ceramides, can also improve permeability barrier function
and alleviate atopic dermatitis. Oral administration of glucosylcer-
amide lowered TEWL in normal mice treated repeatedly with
sodium dodecyl sulfate, by upregulating epidermal differentiation
and tight junction protein expression. Oral glucosylceramide
(0.1%) also improved the epidermal permeability barrier in an
atopic dermatitis model induced by magnesium deﬁciency and
inhibited TNFa expression and inﬂammatory inﬁltrate in a 2,4-
dinitroﬂuorobenzene-induced murine dermatitis model. Orally
taken 1.8 mg ceramide in milk sugar once daily for 2 weeks signiﬁ-
cantly decreased house dust mite-speciﬁc immunoglobulin E (IgE)
production in house dust mite-stimulated cultures of mononuclear
cells, and reduced skin wheal responses to Japanese cedar pollen.
Moreover, oral ceramide signiﬁcantly increased production of the
Th1 cytokines, IFN-g and IL-12, while signiﬁcantly decreasing pro-
duction of the Th2 cytokines, IL-4 and IL-13, in house dust mite-
stimulated cultures. Orally taken ceramide at a dose of 1.8 mg
daily for 2weeks signiﬁcantly lowered TEWL in patients with atopic
dermatitis, in parallel with a 16% reduction in SCORAD scores.40
Collectively, either topical or oral administration of lipids improves
permeability barrier and alleviates disease in atopic dermatitis.
Nonlipid approaches
In addition to lipids, other ingredients that improve the perme-
ability barrier also beneﬁt atopic dermatitis. Topical applications ofCanoderm, a urea-containing cream, twice daily for 20 days not
only reduced TEWL, but also signiﬁcantly increased stratum cor-
neum hydration in atopic dermatitis patients. The skin site treated
with Canoderm was resistant to irritation induced by topical so-
dium lauryl sulphate.41 In addition to the improvement of derma-
titis, barrier enhancing products can also improve the quality of the
life of both patients and patients' parents. For instance, topical urea
containing lotion for 6 weeks improved both SCORAD and the
quality of the life of the patients.42 Likewise, topical barrier
enhancing product for 3 months induced an 89% reduction in
SCORAD and a 52% improvement in the quality of the life of pa-
tients' parents.43 The efﬁcacies of other barrier enhancing products,
including topical peroxisome proliferator-activated receptor (PPAR)
ligand, in treating atopic dermatitis are listed Table 3.40e59
Natural oils
Natural oils, containing a, u, and g linoleic acid, can improve
epidermal permeability barrier function via activation of PPARs.
These linoleic acids can activate PPAR a and g. Activation of PPARs
improves epidermal permeability barrier function and inhibits
cutaneous inﬂammation. Clinical studies showed that topical
application of Stelatopia, containing 2% sunﬂower oleodistillate, for
21 days induced a 75% reduction in SCORAD while CENEO crema,
containing 0.1% hydrocortisone, induced a 70% improvement of
SCORAD. Moreover, the quality of the patient's life improved by 72%
and 65%, following treatments with Stelatopia and CENEO,
respectively.60 Evening primrose oil, a rich source of linoleic acid,
not only improved TEWL and stratum corneum hydration in
normal human skin, but also beneﬁted atopic dermatitis, although
one study showed no effect on atopic dermatitis.61 In addition to
topical applications,62 systemic evening primrose oil improves
epidermal function and serum cytokines in atopic dermatitis.63e67
Orally taken evening primrose oil, containing 160 mg of g linoleic
acid, for an average of 75 days, signiﬁcantly increased serum IFNg
levels (30%), and lowered serum IgE levels by 9%.62 Oral evening
primrose oil for 112 days signiﬁcantly improved dryness, pruritus,
and global assessment scores of atopic dermatitis.64 Likewise, oral
evening primrose oil (Efamol) for 84 days signiﬁcantly improved
atopic dermatitis in 12/13 patients.66 Oral evening primrose oil
induced improvement of SCORAD negatively correlated with the
increased g linoleic acid levels in the serum.67 Similarly, oral sun-
ﬂower oil also beneﬁts atopic dermatitis.64
Antioxidants
The beneﬁts of antioxidant on epidermal permeability barrier and
dermatitis have been well demonstrated. Previous studies
demonstrated that atopic dermatitis was associated negativelywith
intakes of antioxidant-related nutrients.68 We showed that topical
Table 3 Efﬁcacy of barrier enhancing products on atopic eczema.
Products Cases Days of
treatment
SCORAD (%) TEWL (%) Improvement
(% cases)
Adverse effects Refs
TriCeram (Ceragenix Pharmaceuticals,
Inc., Denver, CO, USA)
24 147e147 Y~30 Y~70 92 N/D 33
21 42 Y~45 Y~47 90 N/D 3
3 28 N/D 33 100 N/D 35
Lipid mixture 91 56 N/D ~77 N/D 34
EpiCeram (Promius Pharma, LLC.,
Princeton, NJ, USA)
59 28 51 N/D Dermatitis worsening in 4 individuals 36
19 28 Y~47 N/D 95 Dermatitis worsening in 1 individual 38
13 21 20 N/D No adverse effects 39
MLE (Neopharm Co., Ltd., Yuseong-gu,
Daejeon, Korea)
16 28 Y31 N/D 75 No adverse effects 44
32 28 Y60 Y~24 100 Initial sting feeling in 2 patients 45
Atobarrier (Paciﬁcpharma Corporation,
Seoul, Korea)
30 28 Y75 () N/D Erythema in 1 patient 46
Cetaphil (Galderma Laboratories,
L.P. Fort Worth, TX, USA)
20 28 N/D Y30 N/D No adverse effects 47
24 14 Y19 () N/D N/D 48
5% urea 11 28 14 N/D 100 Feel slight burning in 1 patient 40
Hylatopic 19 28 Y~62 N/D 95 Dermatitis worsening in 1 patient 38
Aquaphor ointment (Beiersdorf AG,
Wilton, CT, USA)
13 21 Y64 N/D Dermatitis worsening in 2 individuals 39
Konjac ceramide 14 56 Y16 Y~20 N/D N/D 45
Canoderm 15 20 N/D Y~20 N/D N/D 46
Iso-urea 50 42 Y20 N/D Erythema in 1 patient 47
10% urea 50 42 Y19 N/D 1 Erythema and 1 had irritant contact dermatitis 47
la Roche posay 191 90 Y89 N/D Eczema ﬂare in 7 patients 48
20% glycerine 68 30 Y85g N/D Worsening in 12% of patients 49
109 30 N/D () N/D N/D 50
4% urea 63 30 Y89g N/D Worsening in 10% of patients 49
109 30 N/D Y~10 N/D N/D 50
5% urea 11 28 14 N/D 100 Feel slight burning in 1 patient 40
20% glycerol 12 28 Y38 Y~29 N/D N/D 51
7 14 Y~64 () N/D N/D 52
Virgin coconut oil 29 56 Y68 Y70 N/D Erythema, pruritus 53
26 28 Y37 N/D N/D 54
Coconut oil 26 28 Y42 N/D N/D 54
Atopiclair (Sinclair Pharma Ltd,
Godalming, UK)
13 21 Y42 N/D Dermatitis worsening in 1 individual 39
72 43 N/D N/D 78a 0.83 adverse events per patient,
stinging (8.3%), burning (6.9%), and fever (6.9%)
55
145 50 N/D N/D 77b N/D 56
20 43 Y~80 90% improvement in IGA 10% of patients had at least 1 adverse event 57
89 42 Y49c N/D 14.6% of patients felt burning 58
E45 cream (Slough, SL1 0NS, UK) 136 84 Y48d N/D N/D 59
Stelatopia 40 21 Y70 N/D None 60
Oral evening primrose oil 14 75 N/D N/D 100 None 63
30 112 Y31e N/D None 64
25 150 Y68 N/D 96 None 65
13 84 N/D N/D 92% None 66
21 84 Y40 N/D 5 drug-related adverse events, including tiredness,
impaired concentration, diarrhea, abdominal cramps,
and pruritus
67
Oral sunﬂower oil 30 112 Y30e N/D None 64
25 150 Y11 N/D 32 None 65
Rosmarinic acid 21 56 Y56 Y17% N/D None 68
Furfuryl palmitate 53 14 Y~27 N/D 29 N/D 69
70
Licochalcone 72 14 N/D N/D 96 1 patient had erythema 71
26 42 Y89 N/D 73 None 72
Vitamin Ef 56 14 Y~46 N/D 70 N/D 69
Oral vitamin E 50 240 N/D N/D 80 None 73
11 60 Y32 N/D N/D N/D 74
Cetaphil ¼ Cetaphil RestoraDerm body moisturizer; MLE ¼ mutil-lammelar emulsion; IGA ¼ investigator's global assessment; PGA ¼ patient global assessment.
a Clear or almost clear
b PGA score
c Visual analogue scale
d Patient eczema severity time
e Improvement of global assessment
f Topical mixture of superoxide dismutase, glycyrrhetinic acid and vitamin E
g Improvement of the dry skin area and severity index.
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epidermal permeability barrier function in inﬂamed skin. Clinical
studies showed that topical applications of 0.3% rosmarinic acid for
4 weeks signiﬁcantly improved scores of erythema, pruritus, and
skin thickness. A > 50% reduction in SCORADwas achieved 8 weeks
after rosmarinic acid treatment.69 Consistently, topical applicationsof other antioxidants, such as furfuryl palmitate and a mixture of
superoxide dismutase and vitamin E, for 7 days, signiﬁcantly low-
ered SCORAD scores and itching.70,71 The efﬁcacy of topical anti-
oxidants in treating atopic dermatitis is comparable to topical
steroids. For example, topical 0.025% licochalcone A achieved a
similar response rate to 1% hydrocortisone (73e96% vs.
G. Man et al. / Dermatologica Sinica 33 (2015) 84e898873e97%).72,73 In addition to topical applications, oral antioxidants,
such as vitamin E and green tea extracts, also improve the perme-
ability barrier and atopic dermatitis. Orally taken, a mixture of
borage oil, vitamin E, and green tea extracts for 18 weeks lowered
TEWL by 18%. Oral vitamin E (400 IU) taken once daily for 8 months
not only improved skin lesions, but also lowered serum IgE levels by
64%.74 Likewise, oral vitamin E (600 IU) taken once daily for 60 days
induced a 32% reduction in SCORAD. A further reduction (96%) in
SCORAD was achieved in patients treated with vitamin E (600 IU)
plus vitamin D (1600 IU).75 These studies indicate that both topical
and oral antioxidants beneﬁt atopic dermatitis.
While enhancing the permeability barrier alone beneﬁts atopic
dermatitis, a combination of a barrier enhancing product and ste-
roids can reduce the dose of steroid usage, consequently resulting
in fewer adverse effects caused by steroids and improvement of the
quality of the patient's life.75,76 Most importantly, both oral and
topical administrations of barrier enhancing products can delay the
relapse77 and prevent the development of atopic dermatitis.78
The efﬁcacy of barrier enhancing products on atopic dermatitis
is dose-dependent. For example, 80% of patients achieved “suc-
cesses” following topical applications of full strength Atopiclair for
22 days, whereas only 26% of patients improved following treat-
ment with low strength Atopiclair.57 It is worth noting that barrier
enhancing products are often mixtures of several ingredients that
beneﬁt the permeability barrier, resulting in a better efﬁcacy. Both
oral and topical administrations of barrier enhancing products are
safer in comparison to conventional regimens, such as steroids and
calcineurin inhibitors.
Conclusion
Epidermal permeability barrier function plays a vital role in the
pathogenesis of atopic dermatitis. A compromised permeability
barrier alone not only induces cutaneous inﬂammation, but also
enhances allergen penetration and colonization of Staphylococcus
aureus. Conversely, improvement of the permeability barrier in-
hibits both inﬂammation and colonization of microbial infections,
resulting from upregulation of antimicrobial peptide expression.
Hence, the strategy of enhancing epidermal permeability barrier
function could be deployed in the management of atopic eczema.
Acknowledgments
This work was supported in part by National Institutes of Health
grants AR and the Medical Research Service, Department of Vet-
erans Affairs Medical Center, San Francisco, CA, USA.
References
1. Scharschmidt TC, Man MQ, Hatano Y, et al. Filaggrin deﬁciency confers a par-
acellular barrier abnormality that reduces inﬂammatory thresholds to irritants
and haptens. J Allergy Clin Immunol 2009;124:496e506.
2. Ye L, Lv C, Man G, Song S, Elias PM, Man MQ. Abnormal epidermal barrier
recovery in uninvolved skin supports the notion of an epidermal pathogenesis
of psoriasis. J Invest Dermatol 2014;134:2843e6.
3. Chamlin SL, Frieden IJ, Fowler A, et al. Ceramide-dominant, barrier-repair lipids
improve childhood atopic dermatitis. Arch Dermatol 2001;137:1110e2.
4. Tsai JC, Feingold KR, Crumrine D, Wood LC, Grunfeld C, Elias PM. Permeability
barrier disruption alters the localization and expression of TNF alpha/protein in
the epidermis. Arch Dermatol Res 1994;286:242e8.
5. Wood LC, Jackson SM, Elias PM, Grunfeld C, Feingold KR. Cutaneous barrier
perturbation stimulates cytokine production in the epidermis of mice. J Clin
Invest 1992;90:482e7.
6. Wood LC, Stalder AK, Liou A, et al. Barrier disruption increases gene expression
of cytokines and the 55 kD TNF receptor in murine skin. Exp Dermatol 1997;6:
98e104.
7. Wood LC, Elias PM, Sequeira-Martin SM, Grunfeld C, Feingold KR. Occlusion
lowers cytokine mRNA levels in essential fatty acid-deﬁcient and normal
mouse epidermis, but not after acute barrier disruption. J Invest Dermatol
1994;103:834e8.8. Wood LC, Elias PM, Calhoun C, Tsai JC, Grunfeld C, Feingold KR. Barrier
disruption stimulates interleukin-1 alpha expression and release from a pre-
formed pool in murine epidermis. J Invest Dermatol 1996;106:397e403.
9. Ito T, Seo N, Yagita H, Tsujimura K, Takigawa M, Tokura Y. Alterations of im-
mune functions in barrier disrupted skin by UVB irradiation. J Dermatol Sci
2003;33:151e9.
10. Nickoloff BJ, Naidu Y. Perturbation of epidermal barrier function correlates
with initiation of cytokine cascade in human skin. J Am Acad Dermatol 1994;30:
535e46.
11. Wood LC, Feingold KR, Sequeira-Martin SM, Elias PM, Grunfeld C. Barrier
function coordinately regulates epidermal IL-1 and IL-1 receptor antagonist
mRNA levels. Exp Dermatol 1994;3:56e60.
12. Lin TK, Man MQ, Santiago JL, et al. Topical antihistamines display potent anti-
inﬂammatory activity linked in part to enhanced permeability barrier function.
J Invest Dermatol 2013;133:469e78.
13. Proksch E, Brasch J. Inﬂuence of epidermal permeability barrier disruption and
Langerhans' cell density on allergic contact dermatitis. Acta Derm Venereol
1997;77:102e4.
14. Proksch E, Brasch J, Sterry W. Integrity of the permeability barrier regulates
epidermal Langerhans cell density. Br J Dermatol 1996;134:630e8.
15. Katoh N, Hirano S, Kishimoto S, Yasuno H. Acute cutaneous barrier perturba-
tion induces maturation of Langerhans' cells in hairless mice. Acta Derm
Venereol 1997;77:365e9.
16. Nishijima T, Tokura Y, Imokawa G, Seo N, Furukawa F, Takigawa M. Altered
permeability and disordered cutaneous immunoregulatory function in mice
with acute barrier disruption. J Invest Dermatol 1997;109:175e82.
17. Mao-Qiang M, Brown BE, Wu-Pong S, Feingold KR, Elias PM. Exogenous non-
physiological vs. physiological lipids: divergent mechanism for correction of
permeability barrier function. Arch Dermatol 1995;131:809e16.
18. Yang L, Mao-Qiang M, Taljebini M, Elias PM, Feingold KR. Topical stratum cor-
neum lipids accelerate barrier repair after tape stripping, solvent treatment and
some but not all types of detergent treatment. Br J Dermatol 1995;133:679e85.
19. Man MQ, Elias P, Thornfeldt CR, Feingold KR. Optimization of stratum corneum
lipids enhances barrier repair. J Invest Dermatol 1996;106:1096e101.
20. Man MQ, Elias P, Feingold KR, et al. A natural lipid mixture improves barrier
function and skin hydration in both human and murine skin. J Soc Cosmet Chem
1997;47:157e66.
21. Ghadially R, Halkier-Sorensen L, Elias PM. Effects of petrolatum on stratum
corneum structure and function. J Am Acad Dermatol 1992;26:387e96.
22. Uchida Y, Behne M, Quiec D, Elias PM, Holleran WM. Vitamin C stimulates
sphingolipid production and markers of barrier formation in submerged hu-
man keratinocyte cultures. J Invest Dermatol 2001;117:1307e13.
23. Hou M, Sun R, Hupe M, et al. Topical apigenin improves epidermal permeability
barrier homoeostasis in normal murine skin by divergent mechanisms. Exp
Dermatol 2013;22:210e5.
24. Hou M, Man M, Man W, et al. Topical hesperidin improves epidermal perme-
ability barrier function and epidermal differentiation in normal murine skin.
Exp Dermatol 2012;21:337e40.
25. Pasonen-Sepp€anen S, Suhonen TM, Kirjavainen M, et al. Vitamin C enhances
differentiation of a continuous keratinocyte cell line (REK) into epidermis with
normal stratum corneum ultrastructure and functional permeability barrier.
Histochem Cell Biol 2001;116:287e97.
26. Hara M, Verkman AS. Glycerol replacement corrects defective skin hydration,
elasticity, and barrier function in aquaporin-3-deﬁcient mice. Proc Natl Acad Sci
U S A 2003;100:7360e5.
27. Fluhr JW, Gloor M, Lehmann L, Lazzerini S, Distante F, Berardesca E. Glycerol
accelerates recovery of barrier function in vivo. Acta Derm Venereol 1999;79:
418e21.
28. Schmuth M, Jiang YJ, Dubrac S, Elias PM, Feingold KR. Thematic review series:
skin lipids. Peroxisome proliferator-activated receptors and liver X receptors in
epidermal biology. J Lipid Res 2008;49:499e509.
29. Peyrin-Biroulet L, Beisner J, Wang G, et al. Peroxisome proliferator-activated
receptor gamma activation is required for maintenance of innate antimicro-
bial immunity in the colon. Proc Natl Acad Sci U S A 2010;107:8772e7.
30. Bourguignon LY, Wong G, Xia W, Man MQ, Holleran WM, Elias PM. Selective
matrix (hyaluronan) interaction with CD44 and RhoGTPase signaling promotes
keratinocyte functions and overcomes age-related epidermal dysfunction.
J Dermatol Sci 2013;72:32e44.
31. Bourguignon LY, Ramez M, Gilad E, et al. Hyaluronan-CD44 interaction stim-
ulates keratinocyte differentiation, lamellar body formation/secretion, and
permeability barrier homeostasis. J Invest Dermatol 2006;126:1356e65.
32. Grether-Beck S, Felsner I, Brenden H, et al. Urea uptake enhances barrier
function and antimicrobial defense in humans by regulating epidermal gene
expression. J Invest Dermatol 2012;132:1561e72.
33. Chamlin SL, Kao J, Frieden IJ, et al. Ceramides-dominant barrier repair lipids
alleviate childhood atopic dermatitis: changes in barrier function provide a
sensitive indicator of disease activity. J Am Acad Dematol 2002;47:198e208.
34. Berardesca E, Barbareschi M, Veraldi S, Pimpinelli N. Evaluation of efﬁcacy of a
skin lipid mixture in patients with irritant contact dermatitis, allergic contact
dermatitis or atopic dermatitis: a multicenter study. Contact Dermatitis
2001;45:280e5.
35. Park KY, Kim DH, Jeong MS, et al. Changes of antimicrobial peptides and
transepidermal water loss after topical application of tacrolimus and ceramide-
dominant emollient in patients with atopic dermatitis. J Korean Med Sci
2010;25:766e71.
G. Man et al. / Dermatologica Sinica 33 (2015) 84e89 8936. Sugarman JL, Parish LC. Efﬁcacy of a lipid-based barrier repair formulation in
moderate-to-severe pediatric atopic dermatitis. J Drugs Dermatol 2009;8:
1106e11.
37. Kucharekova M, Van De Kerkhof PC, Van Der Valk PG. A randomized com-
parison of an emollient containing skin-related lipids with a petrolatum-based
emollient as adjunct in the treatment of chronic hand dermatitis. Contact
Dermatitis 2003;48:293e9.
38. Draelos ZD. A clinical evaluation of the comparable efﬁcacy of hyaluronic acid-
based foam and ceramide-containing emulsion cream in the treatment of mild-
to-moderate atopic dermatitis. J Cosmet Dermatol 2011;10:185e8.
39. Miller DW, Koch SB, Yentzer BA, et al. An over-the-counter moisturizer is as
clinically effective as, and more cost-effective than, prescription barrier creams
in the treatment of children with mild-to-moderate atopic dermatitis: a ran-
domized, controlled trial. J Drugs Dermatol 2011;10:531e7.
40. Miyanishi K, Shiono N, Shirai H, Dombo M, Kimata H. Reduction of trans-
epidermal water loss by oral intake of glucosylceramides in patients with
atopic eczema. Allergy 2005;60:1454e5.
41. Loden M, Andersson AC, Lindberg M. Improvement in skin barrier function in
patients with atopic dermatitis after treatment with a moisturizing cream
(Canoderm). Br J Dermatol 1999;140:264e7.
42. Bissonnette R, Maari C, Provost N, et al. A double-blind study of tolerance and
efﬁcacy of a new urea-containing moisturizer in patients with atopic derma-
titis. J Cosmet Dermatol 2010;9:16e21.
43. Gelmetti C, Boralevi F, Seite S, et al. Quality of life of parents living with a child
suffering from atopic dermatitis before and after a 3-month treatment with an
emollient. Pediatr Dermatol 2012;29:714e8.
44. Lee EJ, Suhr KB, Lee JH, et al. The clinical efﬁcacy of a multi-lamellar emulsion
containing pseudoceramide in Childhood atopic dermatitis: an open crossover
study. Ann Dermatol 2003;154:133e8.
45. Park BD, Youn JK, Lee SH. The clinical efﬁcacy of multi-lamellar emulsion (MLE)
contained pseudoceramide (PC-9S) on atopic dermatitis. J skin Barrier Res
2001;3:18e36.
46. Na JI, Hwang JS, Park HJ, et al. A new moisturizer containing physiologic lipid
granules alleviates atopic dermatitis. J Dermatolog Treat 2010;21:23e7.
47. Simpson E, B€ohling A, Bielfeldt S, Bosc C, Kerrouche N. Improvement of skin
barrier function in atopic dermatitis patients with a new moisturizer con-
taining a ceramide precursor. J Dermatolog Treat 2013;24:122e5.
48. Hon KL, Pong NH, Wang SS, Lee VW, Luk NM, Leung TF. Acceptability and ef-
ﬁcacy of an emollient containing ceramide-precursor lipids and moisturizing
factors for atopic dermatitis in pediatric patients. Drugs R D 2013;13:37e42.
49. Loden M, Andersson AC, Anderson C, et al. A double-blind study comparing the
effect of glycerin and urea on dry, eczematous skin in atopic patients. Acta
Derm Venereol 2002;82:45e7.
50. Loden M, Andersson AC, Andersson C, et al. Instrumental and dermatologist
evaluation of the effect of glycerine and urea on dry skin in atopic dermatitis.
Skin Res Technol 2001;7:209e13.
51. Breternitz M, Kowatzki D, Langenauer M, Elsner P, Fluhr JW. Placebo-
controlled, double-blind, randomized, prospective study of a glycerol-based
emollient on eczematous skin in atopic dermatitis: biophysical and clinical
evaluation. Skin Pharmacol Physiol 2008;21:39e45.
52. Daehnhardt-Pfeiffer S, Surber C, Wilhelm KP, et al. Noninvasive stratum cor-
neum sampling and electron microscopical examination of skin barrier integ-
rity: pilot study with a topical glycerin formulation for atopic dermatitis. Skin
Pharmacol Physiol 2012;25:155e61.
53. Evangelista MT, Abad-Casintahan F, Lopez-Villafuerte L. The effect of topical
virgin coconut oil on SCORAD index, transepidermal water loss, and skin
capacitance in mild to moderate pediatric atopic dermatitis: a randomized,
double-blind, clinical trial. Int J Dermatol 2014;53:100e8.
54. Verallo-Rowell VM, Dillague KM, Syah-Tjundawan BS. Novel antibacterial and
emollient effects of coconut and virgin olive oils in adult atopic dermatitis.
Dermatitis 2008;19:308e15.
55. Boguniewicz M, Zeichner JA, Eichenﬁeld LF, et al. MAS063DP is effective
monotherapy for mild to moderate atopic dermatitis in infants and children: a
multicenter, randomized, vehicle-controlled study. J Pediatr 2008;152:854e9.
56. Abramovits W, Hebert AA, Boguniewicz M, et al. Patient-reported outcomes
from a multicenter, randomized, vehicle-controlled clinical study of
MAS063DP (Atopiclair) in the management of mild-to-moderate atopic
dermatitis in adults. J Dermatolog Treat 2008;19:327e32.
57. Patrizi A, Capitanio B, Neri I, et al. A double-blind, randomized, vehicle-
controlled clinical study to evaluate the efﬁcacy and safety of MAS063DP(ATOPICLAIR) in the management of atopic dermatitis in paediatric patients.
Pediatr Allergy Immunol 2008;19:619e25.
58. Veraldi S, De Micheli P, Schianchi R, Lunardon L. Treatment of pruritus in mild-
to-moderate atopic dermatitis with a topical non-steroidal agent. J Drugs
Dermatol 2009;8:537e9.
59. Mason JM, Carr J, Buckley C, et al. Improved emollient use reduces atopic
eczema symptoms and is cost neutral in infants: before-and-after evaluation of
a multifaceted educational support programme. BMC Dermatol 2013;13:7.
60. De Belilovsky C, Roo-Rodriguez E, Baudouin C, Menu F, Chadoutaud B, Msika P.
Natural peroxisome proliferator-activated receptor-alpha agonist cream
demonstrates similar therapeutic response to topical steroids in atopic
dermatitis. J Dermatolog Treat 2011;22:359e65.
61. Bamford JT, Gibson RW, Renier CM. Atopic eczema unresponsive to evening
primrose oil (linoleic and gamma-linolenic acids). J Am Acad Dermatol 1985;13:
959e65.
62. Gehring W, Bopp R, Rippke F, Gloor M. Effect of topically applied evening
primrose oil on epidermal barrier function in atopic dermatitis as a function of
vehicle. Arzneimittelforschung 1999;49:635e42.
63. Yoon S, Lee J, Lee S. The therapeutic effect of evening primrose oil in atopic
dermatitis patients with dry scaly skin lesions is associated with the normal-
ization of serum gamma-interferon levels. Skin Pharmacol Appl Skin Physiol
2002;15:20e5.
64. Hederos CA, Berg A. Epogam evening primrose oil treatment in atopic
dermatitis and asthma. Arch Dis Child 1996;75:494e7.
65. Senapati S, Banerjee S, Gangopadhyay DN. Evening primrose oil is effective in
atopic dermatitis: a randomized placebo-controlled trial. Indian J Dermatol
Venereol Leprol 2008;74:447e52.
66. Schalin-Karrila M, Mattila L, Jansen CT, et al. Evening primrose oil in the
treatment of atopic eczema: effect on clinical status, plasma phospholipid fatty
acids and circulating blood prostaglandins. Br J Dermatol 1987;117:11e9.
67. Simon D, Eng PA, Borelli S, et al. Gamma-linolenic acid levels correlate with
clinical efﬁcacy of evening primrose oil in patients with atopic dermatitis. Adv
Ther 2014;31:180e8.
68. Oh SY, Chung J, Kim MK, et al. Antioxidant nutrient intakes and corresponding
biomarkers associated with the risk of atopic dermatitis in young children. Eur J
Clin Nutr 2010;64:245e52.
69. Lee J, Jung E, Koh J, Kim YS, Park D. Effect of rosmarinic acid on atopic
dermatitis. J Dermatol 2008;35:768e71.
70. Tripodi S, Di Rienzo Businco A, Panetta V, et al. Lack of efﬁcacy of topical fur-
furyl palmitate in pediatric atopic dermatitis: a randomized double-blind
study. J Investig Allergol Clin Immunol 2009;19:204e9.
71. Patrizi A, Raone B, Raboni R, et al. Efﬁcacy and tolerability of a cream containing
AR-GG27® (sorbityl furfural palmitate) in the treatment of mild/moderate
childhood atopic dermatitis associated with pityriasis alba. A double-blind,
placebo-controlled clinical trial. G Ital Dermatol Venereol 2012;147:1e8.
72. Wananukul S, Chatproedprai S, Charutragulchai W. Randomized, double-blind,
split-side comparison study of moisturizer containing licochalcone vs. 1% hy-
drocortisone in the treatment of infantile seborrhoeic dermatitis. J Eur Acad
Dermatol Venereol 2012;26:894e7.
73. Udompataikul M, Srisatwaja W. Comparative trial of moisturizer containing
licochalcone A vs. hydrocortisone lotion in the treatment of childhood atopic
dermatitis: a pilot study. J Eur Acad Dermatol Venereol 2011;25:660e5.
74. Tsoureli-Nikita E, Hercogova J, Lotti T, Menchini G. Evaluation of dietary intake
of vitamin E in the treatment of atopic dermatitis: a study of the clinical course
and evaluation of the immunoglobulin E serum levels. Int J Dermatol 2002;41:
146e50.
75. Javanbakht MH, Keshavarz SA, Djalali M, et al. Randomized controlled trial
using vitamins E and D supplementation in atopic dermatitis. J Dermatolog
Treat 2011;22:144e50.
76. Msika P, De Belilovsky C, Piccardi N, et al. New emollient with topical
corticosteroid-sparing effect in treatment of childhood atopic dermatitis:
SCORAD and quality of life improvement. Pediatr Dermatol 2008;25:606e12.
77. Loden M, Wiren K, Smerud K, et al. Treatment with a barrier-strengthening
moisturizer prevents relapse of hand-eczema. An open, randomized, pro-
spective, parallel group study. Acta Derm Venereol 2010;90:602e6.
78. Simpson EL, Chalmers JR, Haniﬁn JM, et al. Emollient enhancement of the skin
barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin
Immunol 2014;134:818e23.
